Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes.

作者: A. G. Jones , R. E. J. Besser , T. J. McDonald , B. M. Shields , S. V. Hope

DOI: 10.1111/J.1464-5491.2011.03272.X

关键词: UrineRenal functionMealMedicineInsulinC-peptideEndocrinologyDiabetes mellitusInternal medicineCreatinineGlucose tolerance testGastroenterology

摘要: Diabet. Med. 28, 1034–1038 (2011) Abstract Aims  Serum C-peptide measurement can assist clinical management of diabetes, but practicalities collection limit widespread use. Urine creatinine ratio may be a non-invasive practical alternative. The stability in urine allows outpatient or community testing. We aimed to assess how compared with serum during mixed-meal tolerance test individuals late-onset, insulin-treated diabetes. Methods  correlated the gold standard stimulated fasting and (mixed-meal test, home meal largest meal) 51 subjects diabetes (diagnosis after age 30 years, median age 66 years, at diagnosis 54, 42 Type 2 estimated glomerular filtration rate > 60 ml min−1 1.73 m−2). Results  Ninety-minute is test-stimulated (r = 0.82), breakfast (r = 0.73) (r = 0.71). A (largest cut-off 0.3 nmol/mmol had 100% sensitivity 96% specificity (area under receiver operating characteristic curve = 0.99) identifying without clinically significant endogenous insulin secretion < 0.2 nmol/l). In detecting proposed threshold for requirement (stimulated < 0.6 nmol/l), 0.6 nmol/mmol 92%. Conclusion  patients diagnosed 30 years, well provide alternative measure detect deficiency use routine practice.

参考文章(24)
MARKKU LAAKSO, HELENA SARLUND, TIMO KORHONEN, ERKKI VOUTILAINEN, HELEENA MAJANDER, PAULA HAKALA, MATTI UUSITUPA, KALEVI PYÖRÄLÄ, Stopping insulin treatment in middle-aged diabetic patients with high postglucagon plasma C-peptide. Effect on glycaemic control, serum lipids and lipoproteins. Acta Medica Scandinavica. ,vol. 223, pp. 61- 68 ,(2009) , 10.1111/J.0954-6820.1988.TB15765.X
H. J. Gjessing, L. E. Matzen, O. K. Faber, A. Fr�land, Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia. ,vol. 32, pp. 305- 311 ,(1989) , 10.1007/BF00265547
M. W. Steffes, S. Sibley, M. Jackson, W. Thomas, β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial Diabetes Care. ,vol. 26, pp. 832- 836 ,(2003) , 10.2337/DIACARE.26.3.832
P. M. Clark, Assays for insulin, proinsulin(s) and C-peptide. Annals of Clinical Biochemistry. ,vol. 36, pp. 541- 564 ,(1999) , 10.1177/000456329903600501
C. Hohberg, A. Pfützner, T. Forst, G. Lübben, E. Karagiannis, M. Borchert, T. Schöndorf, Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β‐cell function: results from the PioSwitch Study Diabetes, Obesity and Metabolism. ,vol. 11, pp. 464- 471 ,(2009) , 10.1111/J.1463-1326.2008.00975.X
F. J. Service, R. A. Rizza, B. R. Zimmerman, P. J. Dyck, P. C. O'Brien, L. J. Melton, The Classification of Diabetes by Clinical and C-Peptide Criteria: A prospective population-based study Diabetes Care. ,vol. 20, pp. 198- 201 ,(1997) , 10.2337/DIACARE.20.2.198
Sten Madsbad, Thure Krarup, Peter McNair, Claus Christiansen, Ole K. Faber, Ib Transbøl, Christian Binder, Practical Clinical Value of the C-Peptide Response to Glucagon Stimulation in the Choice of Treatment in Diabetes Mellitus Acta Medica Scandinavica. ,vol. 210, pp. 153- 156 ,(2009) , 10.1111/J.0954-6820.1981.TB09793.X
Linda M. Frazier, Need for Insulin Therapy in Type II Diabetes Mellitus Archives of Internal Medicine. ,vol. 147, pp. 1085- 1089 ,(1987) , 10.1001/ARCHINTE.1987.00370060081015